Bio-Techne develops specialized reagents and diagnostic solutions for global research and clinical markets in the life ...
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Bio-Techne (TECH) is back in focus after institutional ...
Shares of Bio-Techne Corp. TECH rallied 1.82% to $54.87 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.83% to 6,795.99 and ...
What Happened? A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the healthcare industry showing significant job ...
Techne Corporation, the Minneapolis-based biotechnology company that now does business under the “Bio-Techne” brand, recently announced that it’s investing $10 million CyVek, Inc.—and it might ...
Bio-Techne Corp. topped $1 billion in full-year sales for the first time, its latest results showed Thursday, and the Minneapolis-based life science firm said it is beginning a two-year leadership ...
TD Cowen 46th Annual Health Care Conference March 3, 2026 11:10 AM ESTCompany ParticipantsKim Kelderman - CEO, President ...
Techne Corporation—whose longtime CEO resigned in November and protested the search process for his successor—said Monday that it has appointed a new chief executive. Techne, a Minneapolis-based maker ...
The DCF model implemented in this article suggests that Bio-Techne is overvalued by 34.53%. Bio-Techne has allocated significant financial resources to capex. Due to these resources, its revenues ...
More than 600,000 times, researchers have cited Bio-Techne Corp. in academic papers as a manufacturer of tools that helped in their search for new tests and treatments. The company, Minnesota's ...
Shares of Bio-Techne Corp. TECH slid 2.00% to $57.82 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.04% to 6,881.62 and the ...